Harborside


AXIM Biotechnologies, Inc.

AXIM


Canadian symbol: AXIM
US symbol: AXIM

Currency in USD

Valuation Measures4

Market Cap (intraday) 10.56M
Enterprise Value 15.71M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)336.93
Price/Book (mrq)N/A
Enterprise Value/Revenue 564.76
Enterprise Value/EBITDA -1.20

Trading Information

Stock Price History

Beta (5Y Monthly) 2.61
52-Week Change 3-92.39%
S&P500 52-Week Change 3-8.83%
52 Week High 31.0650
52 Week Low 30.0510
50-Day Moving Average 30.0745
200-Day Moving Average 30.2647

Share Statistics

Avg Vol (3 month) 3426.44k
Avg Vol (10 day) 3579.52k
Shares Outstanding 5154.25M
Implied Shares Outstanding 6N/A
Float 886M
% Held by Insiders 147.02%
% Held by Institutions 10.00%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Mar 30, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-29,749.02%

Management Effectiveness

Return on Assets (ttm)-63.32%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)27.81k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)60.46k
EBITDA -6.06M
Net Income Avi to Common (ttm)-17.25M
Diluted EPS (ttm)-0.1260
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)408.04k
Total Cash Per Share (mrq)0
Total Debt (mrq)5.55M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.15
Book Value Per Share (mrq)-0.02

Cash Flow Statement

Operating Cash Flow (ttm)-2.63M
Levered Free Cash Flow (ttm)2.03M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
AXIM
AXIM Biotechnologies
4 days ago
AXIM
AXIM Biotechnologies
3 weeks ago
AXIM
AXIM Biotechnologies
1 month ago
AXIM
AXIM Biotechnologies
1 month ago
AXIM
AXIM Biotechnologies
1 month ago
AXIM
AXIM Biotechnologies
3 months ago
AXIM
AXIM Biotechnologies
3 months ago
AXIM
AXIM Biotechnologies
3 months ago
AXIM
AXIM Biotechnologies
3 months ago
AXIM
AXIM Biotechnologies
4 months ago
AXIM
AXIM Biotechnologies
4 months ago
AXIM
AXIM Biotechnologies
4 months ago
AXIM
AXIM Biotechnologies
5 months ago
AXIM
AXIM Biotechnologies
7 months ago
AXIM
AXIM Biotechnologies
7 months ago
AXIM
AXIM Biotechnologies
7 months ago
AXIM
AXIM Biotechnologies
7 months ago
AXIM
AXIM Biotechnologies
8 months ago
AXIM
AXIM Biotechnologies
8 months ago
AXIM
AXIM Biotechnologies
9 months ago
AXIM
AXIM Biotechnologies
1 year ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
47.02%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by AXIM Biotechnologies, Inc.


AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

SAN DIEGO, May 24, 2022 -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the optimization of a rapid diagnostics test for the quantitative measurement of Ocular Immuno... Read More...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

SAN DIEGO, April 27, 2022 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a rapid quantitative tear test for Lacritin, a tear protein that autonomously promotes tearing ... Read More...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch

AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch

AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab Testing Exec Barry CraigAXIM develops and files for a patent for Novel Tear Collector System SAN DIEGO, Feb. 15, 2022 -- AXIM Biotechnologies,... Read More...
CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies

CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies

SAN DIEGO, Dec. 21, 2021 -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics, oncological research, and dry eye disease, announced today that the Centers for Disease Control and Prevention (CDC) highlighted a study that the Compa... Read More...
AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

AXIM Biotechnologies Applauds FDA’s Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

SAN DIEGO, Nov. 18, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today applauds the FDA on its recent update to its COVID-19 test policies that aims to increase nationwide access to ... Read More...
AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board

AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board

SAN DIEGO, Nov. 02, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today announced it has appointed Michael E. Stern, MS, Ph.D., to its Medical Advisory Board. He joins AXIM’s four oth... Read More...
AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board

AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board

SAN DIEGO, Oct. 20, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced it has appointed Kelly K. Nichols, O.D., M.P.H., Ph.D. to its Medical Advisory Board. Dr. Nichols joi... Read More...
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board

AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board

SAN DIEGO, Oct. 11, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced it has appointed Henry D. Perry, MD to its recently established Medical Advisory Board. He is the thi... Read More...
AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development

AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development

SAN DIEGO, Sept. 15, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19, dry eye disease (DED) and Cancer, today announced that it has appointed Jeffrey A. Busby to Senior Vice President – Business Development. Mr. Busby brings more t... Read More...
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

SAN DIEGO, Aug. 30, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the Company’s manufacturing partner Empowered Diagnostics has filed an amended emergency use a... Read More...
AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants

AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants

SAN DIEGO, May 03, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today a new ELISA test that measures levels of neutralizing antibodies against six common variants of SARS-CoV-2 virus. The Co... Read More...
Coming Soon.

Delayed data (1h)


Share this page